Galapagos' CAR-T Breakthrough: Promising Results in Non-Hodgkin Lymphoma

Galapagos NV, a Belgian biotechnology company, has announced encouraging new results from its ongoing Phase 1/2 study of CD19 CAR T-cell therapy, GLPG5101, in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). The study, ATALANTA-1, has shown promising safety and efficacy data, highlighting the potential of Galapagos' decentralized manufacturing platform for CAR-T therapies.

The decentralized manufacturing platform enables the production of fresh, fit cells within a median vein-to-vein time of seven days, eliminating the need for cryopreservation and transportation. This rapid delivery of high-quality CAR-T products has demonstrated robust in vivo expansion and durable persistence, contributing to high complete response rates in heavily pretreated patients with NHL.

In the ATALANTA-1 study, GLPG5101 showed an encouraging safety profile with most TEAEs of Grade 1 or 2, and the majority of Grade ≥ 3 events being hematological. Two cases of CRS Grade 3 were observed in Phase 1, and one case of ICANS Grade 3 was observed in Phase 2. The objective response rate (ORR) was 86% in the pooled Phase 1 and Phase 2 efficacy analysis set, with complete response rates (CRR) ranging from 56% to 100% across different NHL subtypes.

Durable responses were observed in the majority of responding patients, with 71% of patients in Phase 1 having an ongoing response at data cut-off with median follow-up of 13.1 months. The decentralized manufacturing platform's ability to deliver stem-like early memory cell therapies with robust in vivo expansion and durable persistence may lead to improved patient outcomes and reduced overall cost of care.

Galapagos' decentralized manufacturing platform offers a significant advantage in cost and accessibility compared to centralized manufacturing. By producing fresh, fit cells within a median vein-to-vein time of seven days, Galapagos reduces the need for cryopreservation and shipping, which are major cost drivers in centralized manufacturing. This approach also eliminates the need for bridging therapy, further reducing costs. Moreover, the platform's ability to deliver stem-like early memory cell therapies with robust in vivo expansion and durable persistence may lead to improved patient outcomes, potentially reducing the overall cost of care.

In conclusion, Galapagos' decentralized manufacturing platform for CAR-T therapies, such as GLPG5101, has shown promising results in the treatment of relapsed/refractory non-Hodgkin lymphoma. The platform's ability to deliver fresh, fit cells within a median vein-to-vein time of seven days, resulting in robust in vivo expansion and durable persistence, has contributed to high complete response rates and durable responses in heavily pretreated patients. The decentralized manufacturing platform also offers a significant advantage in cost and accessibility compared to centralized manufacturing, making CAR-T therapies more accessible and affordable for patients with NHL.